Analysts' Actions: JNPR ADSK CMI DVN CNQR
NEW YORK (
) --
CHANGE IN RATINGS
Autodesk
(ADSK) - Get Report
downgraded at Jefferies to Hold from Buy, Jefferies said. $34 price target. Weaker data and limited uplift from suites. Hold rating.
Adtran
(ADTN) - Get Report
upgraded at Mizuho to Buy, Mizuho said. $22 price target. Business will likely bottom out in the fourth quarter.
Cummins
(CMI) - Get Report
upgraded at BMO from Market Perform to Outperform, BMO Capital said. $120 price target. Global growth appears to be stabilizing.
Concur
(CNQR)
downgraded at Piper from Neutral to Underweight, Piper Jaffray said. Valuation call, based on a $49 price target.
Devon Energy
(DVN) - Get Report
downgraded at UBS to Neutral from Buy, UBS said. $60 price target. Long term outlook dims.
Devon Energy downgraded at Citigroup. DVN was downgraded to Neutral from Buy, Citigroup said. $62 price target. Lower costs, but reining in production growth outlook.
Exelon
(EXC) - Get Report
upgraded at UBS to Neutral from Sell, UBS said. $30 price target. Shares now reflect a lower dvidend.
FirstMerit
(FMER)
upgraded at Baird from Underperform to Neutral, Robert Baird said. Valuation call, based on a $13 price target.
Health Net
(HNT)
upgraded at BMO from Underperform to Market Perform, BMO Capital said. $23 price target. Near-term visibility is improving.
Juniper
(JNPR) - Get Report
upgraded at Cantor from Hold to Buy, Cantor Fitzgerald said. $21 price target. Company is cutting costs and is leveraged to higher carrier spending.
Linear Technology
(LLTC)
upgraded at UBS to Buy from Neutral, UBS said. $38 price target. Improved relative growth rate supports raised valuation.
Universal Display
(PANL) - Get Report
downgraded at Wedbush from Outperform to Neutral, Wedbush said. $20 price target. Estimates also cut, as the company has reduced visibility.
Parker Hannifin
(PH) - Get Report
upgraded at BMO to Outperform, BMO Capital said. Valuation call, based on a $94 price target.
Perrigo
(PRGO) - Get Report
downgraded at Caris from Buy to Above Average, Caris & Co. said. $129 price target. Company is seeing slower demand for consumer healthcare and nutritionals.
PSS World Medical
( PSSI) downgraded at UBS to Neutral from Buy, UBS said. $29 price target. 10Q reveals inline results.
Transocean
(RIG) - Get Report
upgraded at Argus from Hold to Buy, Argus said. $62 price target. Company has made several smart strategic decisions.
Rosetta Resources
(ROSE) - Get Report
upgraded at Citigroup to Buy from Neutral, Citigroup said. $60 price target. Solid Q3 beat and 2013 guidance.
Seattle Genetics
(SGEN) - Get Report
downgraded at Cantor from Hold to Sell, Cantor FItzgerald said. $20 price target. Adcetris is growing slower than expected.
STOCK COMMENTS / EPS CHANGES
Accretive Health
(AH)
numbers lowered at OppenheimerShares of AH now seen reaching $15, Oppenheimer said. Estimates also lowered on 3Q results. Outperform rating.
Auxilium Pharma
(AUXL)
numbers lowered at Jefferies. Shares of AUXL now seen reaching $29, Jefferies said. Estimates also lowered on Testim miss. Buy rating.
Cablevision
(CVC)
estimates, target reduced at Morgan Stanley. Shares of CVC now seen reaching $15, according to Morgan Stanley. Estimates also cut, as the company is realizing lower margins. Underweight rating.
HollyFrontier
(HFC) - Get Report
numbers increased at Credit Suisse. HFC estimates were raised through 2015, Credit Suisse said. Company is seeing higher refining growth. Neutral rating and new $53 price target.
Melco Crown
(MPEL)
numbers raised at Citigroup. Shares of MPEL now seen reaching $22.50, Citigroup said. Estimates also increased on Q3 beat. Buy rating.
NYSE Euronext
(NYX)
numbers cut at Citigroup. Shares of NYX now seen reaching $25, Citigroup said. Estimates also lowered as environment remains challenging. Neutral rating.
RealPage
(RP) - Get Report
estimates, target reduced at Credit Suisse. Shares of RP now seen reaching $27, according to Credit Suisse. Estimates also cut, gvien product delays. Outperform rating.
WellPoint
(WLP)
target raised at Jefferies. Shares of WLP now seen reaching $64, Jefferies said. Results show signs of stability. Hold rating.
WellPoint numbers lowered at Oppenheimer. Shares of WLP now seen reaching $73, Oppenheimer said. Estimates also lowered on 3Q results. Outperform rating.
Wellpoint estimates, target boosted at BMO. Shares of WLP now seen reaching $65, according to BMO Capital. Estimates also upped, as the company is keeping a tight lid on costs.
>To submit a news tip, email:
.
READERS ALSO LIKE:
>>Apple Economy's 'Fiscal Cliff' Saved by AT&T's Checkbook
>>Post-Election Selloff Is No Surprise
Follow
TheStreet
on
and become a fan on
This article was written by a staff member of TheStreet.
